AVXL uses the precision medicine word too much but none of the trials use anything related to precision - the patient selection, the dosing cycle - nothing follows precision medicine.
So they can fool/impress few investors but scientific community or BP who really matter in terms of paying do not really believe or care. That is reflected in $3 price.